## LH: Labcorp Holdings Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 1.0% below STRENGTH zone (3.0-6.0%); PEG 1.94 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($244.95)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. Labcorp Takes Strategic Stake in RNA Diagnostics Firm**
- Source: AD HOC NEWS | 20251217T020827 | Somewhat-Bullish | Relevance: 100%
- Labcorp has made a strategic investment in Cofactor Genomics, partnering with Ascension Ventures, to accelerate the expansion of Cofactor's RNA-based diagnostic tools. This move aims to broaden the commercial reach of Cofactor's OncoPrism test, which predicts patient immune responses to immunotherapy. The investment aligns with Labcorp's initiative to enhance advanced diagnostics and precision medicine offerings.

**2. Is the Options Market Predicting a Spike in Labcorp Holdings Stock?**
- Source: TradingView â€” Track All Markets | 20251215T140849 | Somewhat-Bearish | Relevance: 100%
- The options market is showing a high implied volatility for Labcorp Holdings (LH) stock, particularly with the Feb 20, 2026 $135 Call. This suggests investors anticipate a significant price movement, possibly due to an upcoming event. Despite this, analysts currently rate Labcorp Holdings as a Zacks Rank #3 (Hold), with recent downward revisions to earnings estimates.

**3. LabCorp Holdings Inc. (LH) Files Form 8-K with SEC**
- Source: GuruFocus | 20251216T012500 | Neutral | Relevance: 100%
- LabCorp Holdings Inc. (LH) has filed a Form 8-K with the SEC on December 9, 2025, to disclose significant company developments. Although specific details of the filing were not provided in this release, such reports typically announce material events like mergers, leadership changes, or other financial or operational impacts. Investors are encouraged to review the full document on the SEC's website for complete information.

**4. Cofactor Genomics, Inc. announced that it has received funding from Labcorp Holdings Inc., Ascension Ventures, LLC**
- Source: marketscreener.com | 20251215T190838 | Somewhat-Bullish | Relevance: 100%
- Cofactor Genomics, Inc. has secured a new round of funding on December 15, 2025. The investment saw participation from new investor Labcorp Holdings Inc. and existing investor Ascension Ventures, LLC. As part of the transaction, Cofactor Genomics issued convertible preferred shares.

**5. Labcorp Holdings Inc. $LH Shares Bought by Lazard Asset Management LLC**
- Source: MarketBeat | 20251215T080854 | Bullish | Relevance: 100%
- Lazard Asset Management LLC significantly increased its stake in Labcorp Holdings Inc. (NYSE:LH) by 224.1% in the second quarter, bringing its total to 989,433 shares valued at approximately $259.7 million. Labcorp reported strong Q2 earnings, beating EPS estimates, and has issued optimistic FY2025 EPS guidance, although it has seen some insider selling recently. Institutional investors hold a substantial 95.94% of the company's stock, and analysts maintain a "Moderate Buy" rating with an average price target of $299.08.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 2 ($0.00M) |
| Sells | 5 ($3.37M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 43.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 6 |

**Top Holders:**
- Vanguard Group Inc: 11.8% (-0.7%)
- Blackrock Inc.: 9.8% (-10.3%)
- State Street Corpora: 4.6% (-0.8%)
- Victory Capital Mana: 3.2% (+20.0%)
- JPMORGAN CHASE & CO: 2.6% (+64.8%)

### Key Risks

1. Insider selling cluster: $3.4M in recent transactions.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.94 elevated, pricing in significant growth expectations. Forward P/E 14.6x stretched relative to 7% growth. Insider selling cluster ($3.4M in 90 days), potential headwind. Institutional flow bullish (4 buying vs 6 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $21.3B |
| Beta | 0.96 |
| 52W Range | $209.38 - $293.72 |
| Short Interest | 4.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.94 |
| Forward P/E | 14.6 |
| Current P/E | 15.7 |
| YoY Growth | 7.3% |
| EPS Direction | STABLE |

### Technicals

MRS_10 improving modestly (+0.8% over 5 days). Below STRENGTH zone by 2.0pp (needs >3.0% for momentum thesis). MRS_5 (-0.2%) diverging from MRS_10 - short-term weakness emerging. Below SMA200 (0.99x), long-term trend not supportive. OFD pattern: -SUN (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 0.97% (CS: 34) | Neutral |
| RSI_14 | 39.3 | Neutral |
| MACD Histogram | -0.42 | Bearish |
| vs SMA20 | 0.971x | Below |
| vs SMA50 | 0.959x | Below |
| vs SMA200 | 0.993x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $255.75
- **Stop Loss:** $244.95 (4.2% risk)
- **Target:** $266.55 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 99
- **Position Value:** $25,319.25
- **Portfolio %:** 25.32%
- **Risk Dollars:** $1,080.00
- **Risk Per Trade:** 1.08%
- **Modifiers:** L1 90% | L2 120% | Combined 1.08x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | RISK_OFF (HIGH) | 0.90x |
| L2 Sector | TREND (Zone A) | 1.20x |

*RISK_OFF regime with deteriorating conditions. VIX rising to 17.6 (+11.7% over 5 days) signals increasing anxiety, while narrow breadth at 52.6% indicates selective participation. AI infrastructure cost concerns are pressuring tech leadership, creating sector rotation challenges in a late-cycle environment.*

### Earnings

**Next:** 2026-02-05 (Est: $3.94)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $4.14 | $4.18 | +1.0% |
| 2025Q2 | $4.18 | $4.35 | +4.1% |
| 2025Q1 | $3.73 | $3.84 | +2.8% |
| 2024Q4 | $3.39 | $3.45 | +1.7% |

---
*RULE-based L3 | 2026-01-07 01:40 | MRS_10*